Selecta (RUS) Achieves a Technology Transfer Milestone: Synthesizes First Batch of Nanoparticles for the Nicotine Vaccine

14 March 2013

Selecta (RUS), the Russian subsidiary of RUSNANO portfolio company Selecta Biosciences, Inc., announced the successful synthesis of its first batch of tSVP™ nanoparticles using the active component of Selecta’s proprietary nicotine vaccine. The Russian research team reproduced the technology of making tSVP™ nanoparticles after training in Selecta’s main R&D facility near Boston, Massachusetts. The particle size distribution of the batch, which is a critical parameter of nanoparticle medicines, was confirmed by light scattering techniques. Composition and stability of the nanoparticle batch will be analyzed in the company’s Russian laboratories located in the Moscow region. Immunological experiments in animals will also be performed to confirm the biological activity of the batch.

Alexey Nizovtsev, Chief, Laboratory of drug formulations

Alexey Nizovtsev, Chief, Laboratory of drug formulations, demonstrates a sample from the first nanoparticle batch for nicotine vaccine. The nanoparticle size distribution, measured with ZetaPals equipment, is displayed in the background.

The first synthesis of nanoparticles in Russia is an essential step in the transfer and development of Selecta’s unique Synthetic Vaccine Nanoparticle (SVP™) technology platform. “The Russian facility plays an essential role to speed up the development and commercialization of new vaccines for prevention and treatment of life threatening diseases. Our team will focus on smoking cessation, cancer and chronic infections. These are important diseases in Russia. We will develop product candidates for global markets while keeping the Russian patients in mind,” said Dmitry Ovchinnikov, Deputy General Manager at Selecta (RUS).

Selecta’s lead product candidate is SEL-068, a nicotine vaccine for smoking cessation and relapse prevention. A Phase 1 clinical trial was completed in Belgium in early 2013. The company is planning to conduct its next clinical trial in smokers in Russia.

Additional information

  • Alexey Nizovtsev, Chief, Laboratory of drug formulations

    JPG ~3.2 Mb

    2448x3264 pix, 72 dpi

    Alexey Nizovtsev, Chief, Laboratory of drug formulations
    Alexey Nizovtsev, Chief, Laboratory of drug formulations, demonstrates a sample from the first nanoparticle batch for nicotine vaccine. The nanoparticle size distribution, measured with ZetaPals equipment, is displayed in the background

Reference

Selecta (RUS) LLC is a Russian company founded in 2011 by Selecta Biosciences, Inc. and RUSNANO. Selecta (RUS) LLC together with Selecta Biosciences, Inc. will develop a new class of fully synthetic vaccines and immunotherapies based on nanoparticles. The first product which the company plans to develop will be an effective vaccine for the treatment of nicotine addiction. In addition, Selecta (RUS) LLC will participate in programs focusing on development of innovative vaccines in other therapeutic areas such as in cancer, autoimmune diseases, and infectious diseases.

* * *

RUSNANO was founded in March 2011 as an open joint stock company through reorganization of state corporation Russian Corporation of Nanotechnologies. RUSNANO’s mission is to develop the Russian nanotechnology industry through co-investment in nanotechnology projects with substantial economic potential or social benefit. The Government of the Russian Federation owns 100 percent of the shares in RUSNANO. Anatoly Chubais is CEO and chairman of the Executive Board of RUSNANO.

Work to establish nanotechnology infrastructure and training for nanotechnology specialists, formerly conducted by the Russian Corporation of Nanotechnologies, has been entrusted to the Fund for Infrastructure and Educational Programs, a non-commercial fund also established through reorganization of the Russian Corporation of Nanotechnologies.